but also mentions several of Mirati’s other oncology candidates. Top of the list is PRMT5/MTA inhibitor MRTX1719, which BMS said could be a first-in-class therapy for cancers with MTAP deletions ...

Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase ...

PRMT5 inhibitor MRTX1719 for MTAP-deleted cancers, and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported that there was interest in a Mirati buyout, citing Merck as ...

Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...